For the quarter ending 2026-03-31, SRPT made $730,803K in revenue. $330,959K in net income. Net profit margin of 45.29%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 730,803 | 442,934 | 399,356 | 611,091 |
| Cost of sales (excluding amortization of in-licensed rights) | 108,768 | 398,708 | 150,775 | 152,558 |
| Research and development | 153,960 | 325,336 | 218,890 | 204,392 |
| Selling, general and administrative | 108,951 | 128,297 | 91,893 | 137,897 |
| Restructuring charge | - | 1,499 | 40,510 | - |
| Amortization of in-licensed rights | 691 | 677 | 677 | 667 |
| Total cost and expenses | 372,370 | 854,517 | 502,745 | 495,514 |
| Operating income (loss) | 358,433 | -411,583 | -103,389 | 115,577 |
| Gain (loss) on debt extinguishment | - | 155,475* | -138,613 | - |
| Other expense, net | -15,259 | -22,188 | 47,953 | 38,061 |
| Gain from sale of priority review voucher | - | 0* | - | - |
| Total other (gain) income, net | - | 133,287 | -90,660 | - |
| Income (loss) before income tax expense | 343,174 | -278,296 | -194,049 | 153,638 |
| Income tax expense | 12,215 | 4,551 | -14,102 | -43,254 |
| Segment net income (loss) | 330,959 | -282,847 | -179,947 | 196,892 |
| Unrealized gains on investments, net of tax | - | - | 271 | -85 |
| Total other comprehensive income | - | - | 271 | -85 |
| Comprehensive (loss) income | - | - | -179,676 | 196,807 |
| Basic EPS | 3.15 | -2.699 | -1.8 | 2.01 |
| Diluted EPS | 2.88 | -2.94 | -1.8 | 1.89 |
| Basic Average Shares | 104,988,000 | 104,876,000 | 100,237,000 | 98,005,000 |
| Diluted Average Shares | 121,916,000 | 96,258,000 | 100,237,000 | 106,623,000 |
Sarepta Therapeutics, Inc. (SRPT)
Sarepta Therapeutics, Inc. (SRPT)